A groundbreaking study on mice reveals how stress hormones distort memory encoding, causing hazy recollections and fear overgeneralization. This discovery offers potential new avenues for treating PTSD and anxiety disorders, but also raises questions about cannabis use in these conditions.
As the U.S. celebrates Veterans Day, a growing number of war veterans are turning to psychedelic-assisted therapy for relief from PTSD. While clinical trials show promising results, legal and governmental barriers continue to prevent many veterans from accessing these potentially life-changing treatments. This article explores the need for expanded access to psychedelic therapies, the legal hurdles they face, and the ongoing advocacy efforts to provide veterans with the healing they deserve.
The global psychedelic drugs market is set to skyrocket, reaching $10.2 billion by 2028, driven by increasing awareness of mental health needs, progressive regulatory changes, and the medical community’s growing acceptance of psychedelics for therapeutic applications. This article explores the key drivers, trends, and opportunities shaping this rapidly evolving industry.
A growing movement led by veterans is pushing for the decriminalization of psychedelics in Massachusetts, fueled by personal experiences with the healing potential of substances like psilocybin. While advocates highlight the benefits for PTSD and depression, opponents raise concerns about home cultivation and potential risks. This November, voters will decide the fate of Question 4, a ballot measure that could significantly impact mental health treatment options in the state.
Seelos Therapeutics’ stock surged after the company announced a partnership with the US Army to test its intranasal ketamine drug, SLS-002, for PTSD in military personnel and veterans. The trial, funded by the Department of Defense, will evaluate the drug’s effectiveness, safety, and tolerability.
The FDA has requested additional phase 3 trials for MDMA-assisted psychotherapy for PTSD, putting a hold on potential landmark approval. Despite this setback, Lykos Therapeutics remains committed to navigating the FDA’s requirements, while other psychedelic therapies continue to progress in clinical trials.
This personal story recounts the harrowing journey of a young woman who endured years of domestic violence at the hands of her father, witnessing her mother’s struggles to escape the abuse. It explores the complex dynamics within a family trapped by violence, the long-lasting impact of trauma, and the challenges of finding healing and moving forward.
The FDA’s rejection of MDMA-assisted therapy for PTSD has stirred controversy within the psychedelic medicine community, highlighting safety concerns and pushing for regulatory reform. Experts like April Pride, CEO of SetSet, advocate for specialized pathways to expedite research and ensure patient safety while addressing potential risks.
Drug Science and University College London (UCL) have announced a strategic partnership to further investigate the efficacy of MDMA-assisted psychotherapy. This collaboration aims to address concerns raised by the FDA regarding the therapy’s regulation and therapist training, focusing on understanding the intricate interplay between MDMA and various psychotherapeutic approaches. The research will involve studying how different therapeutic modalities impact the effectiveness of MDMA treatment, ultimately aiming to provide a clearer understanding of the therapy’s potential for treating mental health conditions.
Emory University researchers have been awarded a $200,000 grant by the Multidisciplinary Association for Psychedelic Studies (MAPS) to conduct a pilot study exploring the potential of MDMA-assisted therapy in combination with Massed Exposure Therapy (MPE) for treating Post-Traumatic Stress Disorder (PTSD). This study, led by renowned PTSD treatment expert Dr. Barbara Rothbaum, aims to investigate the synergistic effects of these two therapies in helping individuals process traumatic memories and reduce distress.
